GARRE1

Across TCGA pan-cancer cohorts, GARRE1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GARRE1 data layer compared with 32 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GARRE1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GARRE1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where GARRE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.146	0.816	.024	14	view →
LUAD	OS	Median	III,IV	0.213	0.677	.003	9	view →
HNSC	DFS	Tertile	All	1.000	0.868	.004	6	view →
GBM	OS	Quartile	All	0.881	0.702	.031	5	view →
UCEC	OS	Tertile	III,IV	0.485	1.000	.049	4	view →
LSCC	DFS	Tertile	II,III,IV	0.525	1.000	.040	1	view →
CCRCC	DFS	Median	All	0.870	0.715	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GARRE1–PDAC (OS)

Open the PDAC breakdown →